NCT07492394 2026-04-02Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast CancerHebei Medical University Fourth HospitalPhase 2 Recruiting60 enrolled
NCT07330544 2026-01-09A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine TherapyZhejiang Cancer HospitalPhase 2 Recruiting118 enrolled